Introduction {#Sec1}
============

The coronary calcium score (CCS) is known to be a strong predictor for major adverse cardiovascular events \[[@CR1], [@CR2]\]. Computed tomography (CT) is the first modality of choice for assessment of the presence and quantification of calcium in the coronary arteries. The number of CCS examinations with CT is expanding rapidly \[[@CR3]\]. However, due to the expanding use of ionizing radiation in medicine, CT has become the main source of increased population dose in Western countries \[[@CR4]\]. This dose issue is especially important when considering the 2013 guidelines from the American Heart Association that recommend CCS measurements if, after quantitative risk assessment, the risk-based treatment decision is uncertain in asymptomatic adults at intermediate and low-to-intermediate risk \[[@CR5]\].

Recently, iterative reconstruction (IR) has become widely available on commercially available CT systems. IR allows for a dose reduction without the typical decrease in image quality \[[@CR6]--[@CR8]\]. It may therefore be possible to quantify CCS at lower dose levels, when using IR. Recent studies found that application of IR can result in spurious decreases in CCS in comparison with conventionally used filtered back projection (FBP) \[[@CR9]--[@CR11]\]. These effects of dose reduction and IR on CCS can be explained by their effect on image noise. At decreased dose an increase in noise is expected. This increase in noise can be associated with an increase in voxels above the calcium threshold of 130 Hounsfield Units (HU), which in turn increases CCS. Conversely, a decrease in CCS is expected with IR since it reduces noise \[[@CR12]--[@CR15]\].

Moreover, cardiac motion imposes problems for the stability of CCS since calcium can be blurred and CCS can be over- or underestimated, depending on the density of the calcification \[[@CR16]--[@CR18]\]. The combined effects of dose reduction, IR and heart rate on CCS for all major manufacturers have not been investigated before in a phantom study.

Therefore, the objective of this study was to evaluate the influence of dose reduction in combination with IR on CCS of moving calcifications in coronary CT on state-of-the-art CT systems from different manufacturers.

Materials and methods {#Sec2}
=====================

An anthropomorphic chest phantom (Thorax, QRM, Moehrendorf, Germany) with artificial lungs, a spine insert and a shell of soft tissue equivalent material was used \[[@CR16], [@CR17]\]. An extension ring of tissue equivalent material was placed around the chest to simulate an averaged sized patient of 400 × 300 mm (QRM-Extensionring, QRM, Germany) \[[@CR19]\]. The center compartment of the phantom was filled with water in which a motion simulator (Sim2D, QRM, Moehrendorf, Germany) translated an artificial coronary artery with two calcium hydroxyapatite (HA) inserts. The inserts had densities of 196 ± 3, 380 ± 2, 408 ± 2 and 800 ± 2 mg HA/cm^3^ and masses of 38.5 ± 1.7, 74.6 ± 3.1, 80.1 ± 3.3 and 157.1 ± 6.5 mg HA, respectively (Appendices [2](#Sec12){ref-type="sec"}, [3](#Sec13){ref-type="sec"}).

All inserts had equal dimensions; length 10.0 ± 0.1 mm, diameter 5.0 ± 0.1 mm, volume 196.3 ± 8.1 mm^3^. The artificial arteries were linearly translated in the horizontal plane at a velocity of 20 mm/s perpendicular to the scan direction. This velocity is comparable to typical velocities of the left anterior descending and right coronary arteries during the late diastolic scan phase of the R-R interval, at heart rates between 60 and 75 bpm \[[@CR20], [@CR21]\].

In order to assess the influence of IR and dose reduction on CCS in a clinical setting, daily used clinical CT protocols for coronary calcium scoring were used. These protocols were equal to the vendor recommended protocols if available or were adapted based on recommendation by the specific manufacturer consultants. Four different state-of-the-art CT systems (referred to as S1--S4) were used: Discovery CT 750 HD (GE Healthcare, Waukesha, Wisconsin, USA), Brilliance iCT (Philips Healthcare, Best, The Netherlands), Somatom Definition Flash (Siemens Healthcare, Forchheim, Germany) and Aquilion One (Toshiba Medical Systems, Otawara, Japan), respectively (Table [1](#Tab1){ref-type="table"}).

Table 1Acquisition and reconstruction parameters used on CT system S1--S4CT systemS1S2S3S4Tube voltage (kV)120120120120Tube charge per rotation (mA)500185285230Collimation (mm)64  ×  0.625128  ×  0.625128 ×  0.6320 ×  0.5Rotation time (s)0.350.270.280.35Temporal resolution^a^ (ms)17513575175Slice thickness (mm)2.53.03.03.0Increment (mm)2.53.03.03.0KernelStandardXCAB35fFC12Levels of IR20, 60, 100%1, 5, 71, 3, 5weak, standard, strongNoise level (HU)26222824CTDI~vol~ (mGy)10.63.22.86.5SoftwareSmartscore 4.0Heartbeat-CSSyngoVitrea FX 6.5.0^a^As defined in the isocenter

The phantom was scanned at three dose levels by reduction of the tube current: a reference dose at 100% tube current, and at reduced dose levels of 40 and 80% reduced tube current. Each scan was repeated five times with a small translation (2 mm) and rotation (2°) between each scan by manually repositioning the phantom. The internal ECG signal of the motion controller was used to simulate the heart rate of the patient and used as ECG trigger on all four CT systems. The triggering was carefully timed so that data acquisition was during linear motion of the phantom.

Images were reconstructed with FBP, and three increasing levels of IR: the lowest (L1), an intermediate (L2) and the highest level available on the CT system (L3) (Table [1](#Tab1){ref-type="table"}). For each data set the noise level in the images was assessed by calculating the standard deviation in the average Hounsfield value in a uniform water region. The amount of calcium of each insert was quantified as Agatston and mass scores with manufacturer-recommended software (Table [1](#Tab1){ref-type="table"}) with a default threshold of 130 Hounsfield units (HU). A semi-automatic method was used for selecting the calcification by one observer. On each CT system, the mass score calibration factors were determined as described by McCollough et al. \[[@CR19]\]. Although mass scores are not used clinically, they were included for this study because of its potential to compare the score to the physical mass.

The design of this study resulted in 480 calcium scores per CT system (5 acquisitions at 3 dose levels with 4 reconstruction types for 4 calcifications and 2 calcium scores).

Agatston score and mass score were expressed as median and 25th--75th percentile for each calcification insert and CT system. For each insert, CCS from both the iteratively reconstructed and FBP reconstructed data sets for reduced dose levels were compared to the CCS from the FBP reconstructed data sets at reference dose using a Wilcoxon signed rank test. All statistical analyses were performed with SPSS for Windows, version 22.0. A p value of 0.05 was used to determine significant differences.

Results {#Sec3}
=======

Influence of dose reduction and iterative reconstruction on noise {#Sec4}
-----------------------------------------------------------------

For all CT systems and all reconstructions, a decrease in dose resulted in a vendor dependent increase in noise, whereas IR led to a decrease in noise (Fig. [1](#Fig1){ref-type="fig"}). Also, although the CTDI~vol~ differed at most with a factor of 3.8 between the CT systems, the noise levels varied less than 18% at FBP reference dose.

Fig. 1Average noise levels in a uniform water region for images reconstructed with filtered back projection (FBP) and increasing levels of IR L1, L2 and L3 as measured on CT systems S1, S2, S3 and S4. For each combination of reconstruction method and CT system box plots are shown for the average noise level at reference dose, and 40 and 80% reduced dose

Influence of dose reduction on Agatston score with FBP {#Sec5}
------------------------------------------------------

Dose reduction resulted in significant increases in Agatston scores for almost all calcifications and CT systems (Fig. [2](#Fig2){ref-type="fig"}). This increase, in combination with an increase in noise, is depicted in the top row of Fig. [3](#Fig3){ref-type="fig"}.

Fig. 2Influence of dose reduction on Agatston score for S1--S4 with FBP. The movement of the calcification corresponds to displacements seen with heart rates of 60--75 bpm. For calcifications of 38, 74, 80 and 157 mg box plots of the Agatston score at reference dose, and at 40 and 80% reduced dose are shown. Agatston scores are compared with the Agatston score at reference dose using the Wilcoxon signed rank test. Significant different Agatston scores are indicated by *brackets*

Fig. 3Reconstructed images of a 3.0 mm slice of the 38 mg insert moving at 20 mm/s on S2. Data was acquired at reference dose, and at 40 and 80% dose reduction (from *left* to *right*) and reconstructed with filtered back projection and increasing levels of IR L1, L2 and L3 (from *top* to *bottom*). CCS were included as Agatston score/mass score. Noise levels (SD) are expressed as Hounsfield Units. Window center was 90 HU and window width was 750 HU

For S1 at FBP and averaged over all inserts, Agatston scores increased by 8 and 25% at 40 and 80% reduced dose respectively. For the other CT systems similar increases in Agatston scores at FBP were observed at reduced dose with a corresponding average increase of 7 and 64% for S2, 4 and 26% for S3, and 1 and 23% for S4. The largest increase in Agatston score at reduced dose was observed for the 38 mg insert at 80% dose reduction: 58, 160, 48, and 71 for S1--S4, respectively.

Influence of dose reduction on mass score with FBP {#Sec6}
--------------------------------------------------

Also, dose reductions resulted in significantly increased mass scores at FBP for almost all inserts and CT systems, albeit that the increase was smaller than the increase in Agatston scores (Fig. [4](#Fig4){ref-type="fig"}).

Fig. 4Influence of dose reduction on mass score for S1--S4 with FBP. The movement of the calcification corresponds to displacements seen with heart rates of 60--75 bpm. For calcifications of 38, 74, 80 and 157 mg boxplots of the mass score at reference dose, and at 40 and 80% reduced dose are shown. Mass scores are compared with the mass score at reference dose using the Wilcoxon signed rank test. Significant different mass scores are indicated by *brackets*

At 40% reduced dose, mass scores increased on average by 0, 3, 1 and 0% for S1--S4 respectively in comparison with the mass score at reference dose. At 80% reduced dose, mass scores increased 35, 15 and 13% for S2--S4, whereas for S1 the mass score decreased 11%.

Influence of iterative reconstruction on Agatston scores {#Sec7}
--------------------------------------------------------

With increased IR levels, a significant decrease in Agatston scores was observed for almost all calcifications and CT systems (Fig. [5](#Fig5){ref-type="fig"}). This decrease in Agatston score was accompanied by decrease in noise, as can be seen from the left column in Fig. [3](#Fig3){ref-type="fig"}.

Fig. 5Influence of IR on Agatston score for S1--S4 with FBP. The movement of the calcification corresponds to displacements seen with heart rates of 60--75 bpm. For calcifications of 38, 74, 80 and 157 mg boxplots of the Agatston score at FBP and increasing levels of IR (from *left* to *right*: L1, L2 and L3) are shown. Agatston scores are compared with the Agatston score at FBP using the Wilcoxon signed rank test. Significant different Agatston scores are indicated by *brackets*

Averaged over all inserts, Agatston scores for S1 decreased on average 0, 2 and 5% at L1--L3 respectively. For S2 the corresponding decrease was 1, 4, and 5%; for S3 1, 4, and 9% and for S4 1, 4, and 7%. The largest decrease in Agatston score was again observed for the 38 mg calcification: 22% with L3 on S3, and 19% with L3 on S4.

Influence of iterative reconstruction on mass scores {#Sec8}
----------------------------------------------------

The decrease in mass scores at increased levels of IR was smaller than the observed decrease in Agatston scores (Fig. [6](#Fig6){ref-type="fig"}). Mass score decreased on average between 0 and 6% for all CT systems and inserts.

Fig. 6Influence of IR on mass score for S1--S4 with FBP. The movement of the calcification corresponds to displacements seen with heart rates of 60--75 bpm. For calcifications of 38, 74, 80 and 157 mg boxplots of the mass score at FBP and increasing levels of IR (from *left* to *right*: L1, L2 and L3) are shown. Mass scores are compared with the mass score at FBP using the Wilcoxon signed rank test. Significant different mass scores are indicated by *brackets*

Combination of dose reduction and iterative reconstruction on Agatston and mass scores {#Sec9}
--------------------------------------------------------------------------------------

Representative images of the reconstructed datasets are shown in Fig. [3](#Fig3){ref-type="fig"}.

For all four CT systems 40% dose reduction in combination with varying levels of IR did not result in significantly different Agatston and mass scores with respect to the reference dose (Table [2](#Tab2){ref-type="table"}). For 80% dose reduction, only S2 in combination with L2 and L3 did not result in significantly different Agatston scores. For the other CT systems, there was no combination of investigated imaging parameters that resulted in Agatston scores which were unchanged from the reference protocol and dose.

Table 2Reconstructions per CT system S1--S4 that did not result in significantly different Agatston and mass scores at 60--75 bpm and at a dose reduction of 40 and 80% with respect to the FBP-reference doseCT systemDose reduction (%)Agatston scoreMass scoresS140L1FBP, L180n/an/aS240FBP, L1, L2, L3FBP, L1, L2, L380L2, L3L1S340FBP, L1, L2FBP, L1, L2, L380n/aL2, L3S440FBPFBP80n/an/a*FBP*  filtered back projection, *L1, L2, L3* increasing levels of iterative reconstruction

On all CT systems, mass scores generally underestimated the physical mass of the calcifications. Mass scores at FBP and reference dose and deviations from the physical mass are listed in Table [3](#Tab3){ref-type="table"}. Averaged over all inserts the physical mass was underestimated by 23, 12, 30, and 3% for S1--S4 respectively. The largest underestimation was again observed for the 38 mg insert, where the underestimation was 39, 33, 30, and 31%, respectively for S1--S4. At 40% reduced dose the underestimation was 24, 9, 29, and 3%. At 80% reduced dose the underestimation was 24 and 29% on S1 and S3, whereas S2 and S4 showed an overestimation of on average 16 and 9%. The influence of IR on mass scores was relatively small compared to the influence of dose reduction. At the maximum IR level, the underestimation of the physical mass at reference dose was 23, 15, 32, and 8% for S1--S4, respectively (averaged over all inserts).

Table 3Physical mass and corresponding mass scores for all CT systems and calcification massesCT systemPhysical mass (mg)Mass score (mg)Deviation (%)S13823 (20--26)−39 (−47; −32)7458 (54--62)−22 (−27; −16)8070 (60--78)−13 (−25; −3)157125 (108--138)−20 (−31; −12)S23825 (22--26)−33 (−43; −31)7463 (59--68)−15 (−20; −8)8076 (75--79)−5 (−6; −1)157165 (161--175)5 (3; 11)S33820 (16--22)−46 (−57; −42)7449 (47--53)−34 (−37; −28)8062 (59--65)−23 (−26; −19)157131 (128--136)−17 (−19; −13)S43826 (23--29)−31 (−40; −24)7469 (66--72)−7 (−11; −3)8086 (80--94)7 (0; 18)157188 (186--191)20 (19; 21)The mass scores are expressed as median and rangeThe difference between the median and physical mass is also given as median and range

Discussion {#Sec10}
==========

To our knowledge this is the first multivendor study to evaluate the effects of dose reduction and IR on CCS in a dynamic phantom. We have shown that dose reduction in dynamic coronary calcium CT can result in a substantial increase in CCS, whereas the use of IR results in modestly decreased CCS. The most important clinically relevant finding is the ability to reduce dose by 40% in routinely used clinical protocols on state-of-the-art CT systems of four major manufacturers, without compromising the calcium score. This result is not only valid for high plaque burden, but also for the clinically more important mild to moderate coronary plaque burden, represented by the 38 and 74 mg calcifications respectively.

Since risks of radiation dose increase with growing numbers of CT examinations, dose reduction techniques in CCS are highly relevant. Because new guidelines recommend CCS measurements if, after quantitative risk assessment, the risk-based treatment decision is uncertain, it is expected that the number of CT examinations for CCS will further increase in coming years \[[@CR5]\]. In the current study we found for all CT systems that dose reductions of 40%, in combination with the in Table [2](#Tab2){ref-type="table"} specified reconstruction methods, did not significantly affect Agatston scores. For one vendor, the Agatston scores were even similar at 80% reduced dose, and for two vendors there was no significant difference in mass scores at 80% reduced dose in combination with IR.

These results are consistent with those of Hecht et al. \[[@CR15]\] who showed in a patient study that for one CT system (equal to S2) CCS can be performed at reduced radiation dose (50%) in combination with IR, without significantly affecting Agatston scores \[[@CR15]\]. Ode et al. showed, for a pulsating phantom at 60 bpm and one CT system (similar to S4), that increased IR resulted in decreased Agatston scores, which is in agreement with our results \[[@CR22]\]. In comparison with full dose FBP, Agatston scores were not influenced at IR levels L2 and L3 in combination with dose reduction up to 75%, for all used calcifications combined. In our study however, Agatston scores at 40 and 80% reduced dose were found to be significantly different for all IR levels. The reason for this difference is that we only included combinations of dose reduction and IR, when valid for all calcifications separately. Our results also correspond well with a recent study which showed that IR has the potential to reduce radiation dose with 27--54% using a non-dynamic phantom and the same CT systems \[[@CR23]\]. With non-dynamic ex vivo human hearts it was shown that a dose reduction of 80% was possible for the four CT systems \[[@CR23], [@CR24]\]. This study, however, used static calcifications, did not report on a reference standard of true calcification mass, and used a small-sized phantom. In our dynamic study, we found that a dose reduction of 80% was only feasible for one CT system, and a dose reduction of 40% was possible for all four CT systems, even for low-density calcifications in combination with specific reconstruction methods. Because iterative CT reconstruction significantly reduces calcium scores \[[@CR10], [@CR25]\], which potentially alters perceived cardiovascular risk \[[@CR26]\], this effect may be counter balanced by the use of reduced dose levels. Moreover, it has been shown that the application of IR significantly improves objective image quality \[[@CR12]\], and does not alter quantitative analysis of coronary plaque volume, composition and luminal area \[[@CR27]\].

Our results showed a relatively large variation in calcium scores between the CT systems, with Agatston scores ranging from 450 to 738, for the 157 mg calcification. This is in line with previous studies that found that state-of the-art CT scanners of different manufacturers produce substantially different Agatston scores, which can result in reclassification of patients to high- or low-risk categories in up to 6.5% of the cases \[[@CR28]\]. Moreover, mass scores generally underestimated the physical mass of the inserts by 3--23% depending on the specific CT system. Underestimations of the physical mass up to 68% were also observed with a static calcium phantom \[[@CR29]\].

Reference dose levels, from routinely used clinical protocols of the four high-end CT systems, showed large differences (2.8--10.6 mGy). Despite of these differences in dose levels, similar noise levels were found (22--28 HU). It is important to note, however, that noise is not only determined by dose, but---among other parameters---also by reconstruction kernel. A sharper kernel results in more noise as compared to a softer kernel, if the dose levels are the same. Therefore, different CT acquisition and reconstruction settings may result in different dose levels but similar noise levels. The noise levels behaved as expected as a function of dose reduction and IR: noise levels increased at decreasing dose, and noise levels decreased at increased IR. Our findings indicate that even in the presence of comparable noise levels CCS differed up to 39% between different CT systems at full dose FBP. These differences are surprising for a relatively straightforward metric as the coronary calcium score.

This study has limitations. First, this was an in-vitro study with artificial arteries with calcified inserts. However, the inserts where embedded in an anthropomorphic phantom and were translated at a velocity that is generally observed in in-vivo studies, and the masses of the inserts were in range with calcium masses clinically detected in patients \[[@CR30]\]. Second, movement of the calcifications was linear. In vivo, coronary arteries perform a complex movement in three dimensions, which was not feasible in our setup. However, because a linear movement can approximate the movement in 3D during the acquisition time of the CT data, we estimate that addition of 3D movement would result in minor changes in our results. Third, analysis on the inter and intra variability for the different CT systems has not been performed. The associated CT specific correlation between noise reduction and CCS accuracy was also not within the scope of this study. However, these analysis can answer questions about current practice. For example specificity, sensitivity, variations in CCS score between different vendors and the possibility to reduce dose without impact on the metric. Finally, only sequential scan modes were used. With the current appearance of high-pitch spiral mode scanning for coronary calcium it would be interesting to assess the differences in the accuracy of coronary calcium assessment between sequential and high-pitch spiral mode. However, that was not within the scope of this study.

We conclude that for all CT systems a dose reduction of 40% in combination with specific reconstruction gives a CCS comparable for reference protocols. For several systems, even higher dose reductions are possible. Dose reduction results in increased noise and consequently increased CCS, whereas increased IR results in decreased CCS. Mass scores generally underestimated physical mass of the calcifications.

Appendix 1 {#Sec11}
==========

See Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}.

Table 4Agatston scores (median and range) for all CT systems, calcification masses, reconstructions and dose valuesCT systemMassRecon.Full dose40% reduction80% reductionMedian (range)p valueMedian (range)p-valueMedian (range)p-valueS138 mgFBP95\
(92--109)Ref109\
(99--127)0.041150\
(137--159)0.043L197\
(92--107)0.59396\
(93--108)0.686139\
(133--147)0.043L293\
(88--98)0.04293\
(90--105)0.141121\
(94--128)0.225L391\
(87--95)0.04291\
(88--95)0.08094\
(88--107)0.06674 mgFBP328\
(315--345)Ref323\
(308--336)0.042331\
(320--345)0.684L1328\
(311--345)0.102318\
(308--337)0.068325\
(319--332)0.498L2326\
(306--336)0.042305\
(296--311)0.043314\
(303--326)0.225L3305\
(302--323)0.043302\
(294--307)0.043306\
(299--311)0.04280 mgFBP388\
(336--446)Ref377\
(347--464)0.893419\
(388--465)0.043L1388\
(333--441)0.068376\
(329--459)0.343409\
(381--459)0.043L2381\
(327--441)0.042372\
(325--452)0.078405\
(370--446)0.046L3375\
(322--435)0.043362\
(317--445)0.043398\
(366--433)0.225157 mgFBP497\
(490--636)Ref595\
(561--638)0.043664\
(602--707)0.080L1492\
(473--631)0.041586\
(559--623)0.080644\
(591--692)0.080L2480\
(453--618)0.043573\
(538--596)0.138629\
(580--667)0.080L3463\
(432--608)0.043569\
(528--584)0.345616\
(566--646)0.138S238 mgFBP102\
(90--125)Ref106\
(89--144)0.854265\
(202--331)0.043L199\
(89--107)0.042103\
(84--112)0.686132\
(108--209)0.043L295\
(89--107)0.04396\
(82--111)0.104124\
(84--205)0.225L395\
(89--104)0.04295\
(69--108)0.08099\
(70--203)0.89374 mgFBP313\
(297--342)Ref336\
(306--351)0.138411\
(382--514)0.043L1312\
(294--340)0.041323\
(307--347)0.225343\
(307--421)0.043L2295\
(284--335)0.043317\
(297--344)1.000315\
(294--364)0.892L3291\
(283--329)0.043311\
(287--337)0.785309\
(287--354)0.89380 mgFBP350\
(313--390)Ref374\
(331--425)0.225448\
(438--456)0.043L1349\
(307--383)0.066376\
(328--423)0.225389\
(371--404)0.043L2348\
(305--369)0.042368\
(322--412)0.893361\
(346--373)0.893L3332\
(299--371)0.068364\
(299--408)0.893340\
(334--364)0.500157 mgFBP505\
(439--571)Ref551\
(449--657)0.225690\
(472--714)0.080L1499\
(444--568)0.416543\
(449--652)0.345561\
(469--652)0.225L2494\
(432--567)0.043532\
(442--643)0.345544\
(455--631)0.345L3490\
(433--566)0.043520\
(434--625)0.345528\
(446--613)0.500S338 mgFBP102\
(80--120)Ref105\
(93--132)0.225151\
(145--172)0.043L1101\
(77--118)0.10993\
(87--116)0.892142\
(135--161)0.043L293\
(73--101)0.04387\
(75--97)0.080111\
(92--117)0.225L380\
(72--93)0.04377\
(70--95)0.08088\
(85--99)0.22374 mgFBP278\
(275--309)Ref294\
(226--311)0.498303\
(287--377)0.042L1274\
(274--305)0.042292\
(224--310)0.715295\
(282--367)0.042L2273\
(267--298)0.042267\
(202--308)0.225281\
(248--324)0.892L3270\
(262--278)0.043264\
(198--302)0.080269\
(237--312)0.34580 mgFBP320\
(303--356)Ref338\
(321--354)0.138397\
(337--495)0.043L1318\
(298--355)0.042332\
(313--338)0.686391\
(334--415)0.043L2318\
(291--330)0.042322\
(306--331)0.893362\
(311--378)0.080L3303\
(286--325)0.043311\
(300--318)0.225339\
(204--370)0.686157 mgFBP450\
(420--460)Ref459\
(425--461)0.465561\
(517--579)0.043L1446\
(412--456)0.042451\
(417--453)0.893546\
(501--552)0.043L2434\
(403--444)0.043432\
(398--439)0.345516\
(469--524)0.043L3414\
(398--437)0.042420\
(392--435)0.043484\
(450--500)0.043S438 mgFBP109\
(93--125)Ref107\
(94--130)0.500186\
(166--204)0.043L1105\
(93--113)0.197103\
(77--107)0.22599\
(83--112)0.225L296\
(88--111)0.080100\
(76--104)0.06898\
(80--112)0.225L388\
(82--103)0.04397\
(75--102)0.04382\
(75--94)0.04374 mgFBP372\
(346--391)Ref367\
(335--397)0.223438\
(367--462)0.043L1370\
(334--389)0.336350\
(309--377)0.043314\
(300--363)0.043L2365\
(327--384)0.042350\
(308--355)0.042308\
(297--357)0.043L3352\
(309--367)0.043344\
(298--350)0.043296\
(293--314)0.04380 mgFBP452\
(427--503)Ref467\
(396--494)0.225488\
(459--494)0.892L1462\
(423--476)0.345445\
(392--453)0.043402\
(370--438)0.080L2452\
(421--480)0.068439\
(390--451)0.043399\
(367--438)0.080L3438\
(420--448)0.042411\
(390--446)0.043370\
(349--425)0.043157 mgFBP738\
(672--752)Ref706\
(603--743)0.078716\
(659--749)0.500L1736\
(657--744)0.041698\
(597--726)0.042666\
(585--675)0.043L2730\
(657--742)0.066697\
(600--724)0.043660\
(585--668)0.042L3736\
(660--748)0.042694\
(606--725)0.042654\
(584--661)0.043P values of the Wilcoxon signed rank test are given for each combination of dose value and reconstruction type, compared to the reference FBP full dose value

Table 5Mass scores (median and range) for all CT systems, calcification masses, reconstructions and dose valuesCT systemMassRecon.Full dose40% reduction80% reductionMedian\
(range)p valueMedian\
(range)p valueMedian\
(range)p valueS138 mgFBP23\
(20--26)Ref25\
(20--27)0.05926\
(21--30)0.041L123\
(19--26)0.31724\
(21--26)0.15728\
(25--29)0.041L222\
(18--25)0.03423\
(19--25)0.04327\
(24--27)0.038L322\
(16--24)0.03922\
(16--24)0.03926\
(21--26)0.41474 mgFBP58\
(54--62)Ref58\
(45--62)0.18043\
(36--54)0.042L157\
(52--62)0.05958\
(52--62)0.18048\
(44--58)0.039L257\
(55--61)0.15758\
(52--61)0.10953\
(50--59)0.039L357\
(50--60)0.04157\
(53--60)0.03858\
(50--58)0.04380 mgFBP70\
(60--78)Ref71\
(61--74)0.89256\
(50--64)0.043L169\
(61--78)1.00070\
(65--74)1.00058\
(51--66)0.042L271\
(69--76)0.68469\
(65--74)0.89367\
(64--72)0.414L370\
(64--76)0.68070\
(66--73)1.00069\
(62--73)0.785157 mgFBP125\
(108--138)Ref110\
(105--120)0.225111\
(108--116)0.078L1125\
(108--138)0.317113\
(108--118)0.223110\
(107--116)0.080L2132\
(115--141)0.077112\
(104--122)0.225111\
(105--114)0.080L3135\
(118--142)0.080119\
(112--124)0.225112\
(111--127)0.225S238 mgFBP25\
(22--26)Ref24\
(22--30)0.85443\
(34--55)0.043L125\
(21--26)0.15723\
(21--28)0.46528\
(21--38)0.225L224\
(20--26)0.18022\
(19--27)0.25725\
(19--37)0.500L323\
(20--26)0.06322\
(18--27)0.17624\
(17--37)0.58174 mgFBP63\
(59--68)Ref65 (61--70)0.27981\
(74--101)0.043L162\
(59--68)0.15764\
(59--69)0.89264\
(61--80)0.684L261\
(58--67)0.03863\
(58--68)0.41460\
(58--79)0.893L360\
(58--66)0.04162\
(58--67)0.22160\
(57--77)1.00080 mgFBP76\
(75--79)Ref81\
(73--86)0.13892\
(86--93)0.043L175\
(75--78)0.15780\
(72--85)0.27976\
(71--78)0.276L275\
(74--78)0.02579\
(70--84)0.68372\
(68--74)0.042L375\
(74--76)0.10978\
(70--83)1.00071\
(66--73)0.042157 mgFBP165\
(161--175)Ref174\
(163--187)0.144200\
(181--207)0.042L1164\
(161--174)0.063170\
(161--186)0.225164\
(162--188)0.336L2163\
(159--173)0.025169\
(160--184)0.498161\
(159--185)0.498L3163\
(159--173)0.038168\
(159--182)0.498160\
(157--183)0.345S338 mgFBP20\
(16--22)Ref20\
(18--21)0.49624\
(23--28)0.042L120\
(16--21)0.31719\
(17--20)0.85423\
(22--25)0.042L220\
(15--21)0.08318\
(16--19)0.19720\
(19--20)0.684L319\
(14--20)0.03817\
(15--18)0.10417\
(16--18)0.22574 mgFBP49\
(47--53)Ref50\
(39--54)0.71355\
(46--60)0.141L148\
(47--53)0.31750\
(38--53)1.00054\
(44--59)0.225L247\
(47--53)0.18049\
(38--53)0.41450\
(42--55)1.000L347\
(46--53)0.05948\
(37--52)0.13146\
(39--52)0.17680 mgFBP62\
(59--65)Ref64\
(59--65)0.35772\
(62--93)0.068L161\
(59--65)0.31763\
(59--65)0.41671\
(61--78)0.080L262\
(58--65)0.08362\
(58--64)1.00066\
(58--70)0.176L362\
(58--65)0.08362\
(57--64)0.89264\
(56--65)0.713157 mgFBP131\
(128--136)Ref132\
(129--134)0.496145\
(138--150)0.043L1131\
(127--136)0.317131\
(128--133)1.000139\
(135--146)0.043L2130\
(127--135)0.025130\
(127--132)0.680133\
(131--141)0.273L3130\
(127--135)0.025130\
(126--132)0.257130\
(126--137)0.854S438 mgFBP26\
(23--29)Ref27\
(23--28)0.70532\
(29--41)0.041L125\
(22--28)0.10226\
(21--27)0.10223\
(19--27)0.066L225\
(21--28)0.10225\
(20--26)0.06823\
(18--24)0.068L323\
(20--26)0.03424\
(20--27)0.04221\
(17--25)0.04374 mgFBP69\
(66--72)Ref67\
(66--69)0.28578\
(74--80)0.043L166\
(65--69)0.06664\
(61--66)0.04262\
(60--66)0.042L265\
(64--68)0.04264\
(61--67)0.03960\
(59--61)0.043L365\
(61--66)0.04262\
(59--65)0.04359\
(56--62)0.04280 mgFBP86\
(80--94)Ref87\
(81--88)0.49696\
(93--101)0.039L185\
(79--89)0.05982\
(76--88)0.04279\
(76--79)0.043L284\
(78--87)0.03981\
(76--85)0.04178\
(75--80)0.043L382\
(76--86)0.03479\
(74--84)0.04274\
(72--80)0.042157 mgFBP188\
(186--191)Ref185\
(176--192)0.102197\
(189--201)0.043L1186\
(183--194)0.216179\
(169--186)0.043168\
(167--173)0.042L2185\
(182--187)0.039178\
(169--183)0.043166\
(165--171)0.042L3181\
(178--186)0.039175\
(168--179)0.041162\
(160--168)0.043P values of the Wilcoxon signed rank test are given for each combination of dose value and reconstruction type, compared to the reference FBP full dose value

Appendix 2 {#Sec12}
==========

See Fig. [7](#Fig7){ref-type="fig"}.

Fig. 7Anthropomorphic chest phantom with extension ring and motion controller (QRM, Moehrendorf, Germany). An artificial coronary artery moved in the horizontal plane inside the water tank in the center of the chest phantom

Appendix 3 {#Sec13}
==========

See Fig. [8](#Fig8){ref-type="fig"}.

Fig. 8The cylindrical artificial coronary artery contained two calcified inserts with a diameter of 5.0 ± 0.1 mm and a length of 10.0 ± 0.1 mm as indicated

CCS

:   Coronary calcium score

CT

:   Computed tomography

FBP

:   Filtered back projection

HA

:   Hydroxyapatite

HU

:   Hounsfield units

IR

:   Iterative reconstruction
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